We compared patients with ( n = @ ) or without AST ( n = @,@ ) regarding baseline , clinical , and procedural characteristics and antithrombotic treatment strategies ( choice of P@Y@ inhibitor , post-primary PCI bivalirudin infusion dose -LSB- @ mg/kg/h , or BIV-LOW -RSB- vs. -LSB- @ mg/kg/h , or BIV-PCI -RSB- vs. heparin GPI ) .